Trial Profile
A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Effect of Symbicort® and Pulmicort® on HAT and HDAC Expression and Activity in Induced Sputum Cells Obtained From COPD Patients.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Budesonide/formoterol (Primary) ; Budesonide
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- 05 Aug 2019 Status changed from completed to withdrawn prior to enrolment.
- 03 Jun 2015 New trial record